Biopharma

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

AI-Driven Amino Acid Drugs Surface as a Promising Treatment for Eye Conditions

The rapid evolution of artificial intelligence (AI) promises to revolutionize multiple sectors, and one area seeing tangible benefits is drug development. Historically, the creation of new medicines was a time-consuming endeavor, but AI-driven amino acid research is proving to accelerate the early developmental stages and get drugs to the market faster. Researchers at the Wilmer…